Tyrosine Kinase Inhibitors: Mechanism and Examples

Tyrosine kinase inhibitors (TKIs) are small-molecule anticancer drugs that block the catalytic activity of tyrosine kinases — enzymes that transmit growth and survival signals by transferring phosphate to tyrosine residues. By interrupting dysregulated kinase signalling that a tumour depends on, TKIs can suppress proliferation and survival of malignant cells with relative selectivity compared with cytotoxic chemotherapy.

Definition

A tyrosine kinase inhibitor is a small molecule that binds a protein tyrosine kinase — most commonly within its ATP-binding pocket — and blocks phosphotransfer, thereby interrupting the downstream signalling that drives tumour-cell proliferation and survival.

Scope

This topic covers what tyrosine kinases are, how their dysregulation drives cancer, how small-molecule inhibitors act at the ATP-binding site, the distinction between competitive and covalent or allosteric inhibitors, the problem of acquired resistance, and representative examples. It is reference-educational and does not provide dosing or treatment recommendations.

Core questions

• How do tyrosine kinases transmit oncogenic signals, and how does inhibition interrupt them?
• What is the difference between ATP-competitive, allosteric, and covalent (irreversible) inhibitors?
• Why do tumours develop resistance to TKIs, and through what mechanisms?
• How does target selectivity relate to both efficacy and off-target toxicity?

Key concepts

• Protein tyrosine kinase and phosphotransfer
• ATP-binding (catalytic) pocket
• ATP-competitive inhibition
• Allosteric and covalent (irreversible) inhibitors
• BCR-ABL and chronic myeloid leukaemia
• Gatekeeper mutation and acquired resistance
• Receptor versus non-receptor tyrosine kinases
• Selectivity and off-target effects

Key theories

Oncogene addiction

Tumours dependent on a single constitutively active tyrosine kinase, such as BCR-ABL in chronic myeloid leukaemia, are exquisitely sensitive to selective inhibition of that kinase, which provided the clinical proof of principle for the drug class.

Mechanisms

Tyrosine kinases catalyse transfer of the γ-phosphate of ATP onto tyrosine residues of substrate proteins, switching on signalling cascades that promote proliferation and survival. In many cancers a kinase is constitutively activated — by gene fusion (for example BCR-ABL), activating mutation, or receptor overexpression — so that signalling runs unchecked. Most small-molecule TKIs are ATP-competitive: they occupy the kinase's ATP-binding pocket and prevent phosphotransfer, shutting down the downstream cascade. Some agents bind allosteric sites or form covalent bonds with a cysteine residue to achieve irreversible inhibition. Because the ATP pocket is conserved across the kinome, designing inhibitors with adequate selectivity is a central challenge, and off-target kinase inhibition contributes to class-typical toxicities. Resistance commonly emerges through secondary mutations (such as gatekeeper substitutions that reduce drug binding), amplification of the target, or activation of bypass signalling pathways.

Clinical relevance

TKIs are a mainstay of targeted oncology and exemplify how knowledge of a tumour's driver kinase guides therapy selection. This entry explains the mechanism and conceptual basis of the class to support understanding of how these drugs are categorised and act; it is not a basis for individual treatment decisions and contains no dosing information.

Evidence & guidelines

The clinical proof of principle came from the demonstration that imatinib, a selective BCR-ABL inhibitor, produced high response rates in chronic myeloid leukaemia, establishing that inhibiting a single driver kinase can transform outcomes. Subsequent mechanistic reviews catalogued the broader class of small-molecule kinase inhibitors and the structural basis of ATP-competitive and covalent inhibition.

History

Recognition in the 1980s and 1990s that aberrant tyrosine-kinase signalling drives malignant transformation motivated the search for selective inhibitors. The 2001 clinical reports of imatinib in BCR-ABL-positive chronic myeloid leukaemia marked the arrival of the class and reframed kinase inhibition as a tractable therapeutic strategy. Later generations of inhibitors addressed resistance mutations and expanded the range of targetable kinases.

Debates

How much selectivity is desirable in a kinase inhibitor?

Highly selective inhibitors limit off-target toxicity but may be undermined by single resistance mutations, whereas multi-targeted inhibitors can broaden activity and counter bypass signalling at the cost of more off-target effects; the optimal balance remains a design question.

Key figures

• Brian Druker
• Nicholas Lydon
• Charles Sawyers
• Nathanael Gray

Seminal works

• druker-2001
• zhang-2009

Frequently asked questions

Why are most tyrosine kinase inhibitors described as ATP-competitive?

Most TKIs bind within the kinase's ATP-binding pocket and compete with ATP, preventing the enzyme from transferring phosphate to its substrate and thereby shutting down the signalling cascade.

Why do tumours often become resistant to a tyrosine kinase inhibitor?

Resistance commonly arises from secondary mutations that reduce drug binding (such as gatekeeper mutations), amplification of the target kinase, or activation of alternative bypass signalling pathways.